open access

Vol 10, Supp. C (2019)
Case report
Get Citation

Efficacy of brentuximab vedotin in the fourth-line treatment of primary resistant Hodgkin lymphoma

Beata Kania-Zembaczyńska1
DOI: 10.5603/Hem.2019.0022
Affiliations
  1. Oddział Onkologiczny i Hematoonkologiczny, Beskidzkie Centrum Onkologii — Szpital Miejski, ul. Wyzwolenia 18, 43–382 Bielsko-Biała, Poland

open access

Vol 10, Supp. C (2019)
CASE REPORTS

Abstract

Patients with relapsed or primary resistant Hodgkin lymphoma (HL) who do not qualify for high-dose chemotherapy with a transplant of autologous hematopoietic stem cell transplantation (auto-HSCT) have poor prognosis. The use of new drugs such as brentuximab vedotin, anti-PD-L1 antibodies enables remission and sustained response in this difficult to treat group of patients. Brentuximab vedotin is a conjugate of anti-CD30 and auristatin E antibodies. The drug was registered by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2012 to treat patients with recurrent or resistant HL. In Poland, this drug is available in the National Health Fund drug program for patients after autologous peripheral blood stem cell transplantation or after at least two lines of chemotherapy, when auto-HSCT is not a valid treatment option. This case illustrates the effectiveness of brentuximab vedotin in the fourth line of primary resistant HL treatment.

Abstract

Patients with relapsed or primary resistant Hodgkin lymphoma (HL) who do not qualify for high-dose chemotherapy with a transplant of autologous hematopoietic stem cell transplantation (auto-HSCT) have poor prognosis. The use of new drugs such as brentuximab vedotin, anti-PD-L1 antibodies enables remission and sustained response in this difficult to treat group of patients. Brentuximab vedotin is a conjugate of anti-CD30 and auristatin E antibodies. The drug was registered by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2012 to treat patients with recurrent or resistant HL. In Poland, this drug is available in the National Health Fund drug program for patients after autologous peripheral blood stem cell transplantation or after at least two lines of chemotherapy, when auto-HSCT is not a valid treatment option. This case illustrates the effectiveness of brentuximab vedotin in the fourth line of primary resistant HL treatment.

Get Citation

Keywords

Hodgkin lymphoma, high-dose chemotherapy, brentuximab vedotin

About this article
Title

Efficacy of brentuximab vedotin in the fourth-line treatment of primary resistant Hodgkin lymphoma

Journal

Hematology in Clinical Practice

Issue

Vol 10, Supp. C (2019)

Article type

Case report

Pages

26-29

Page views

333

Article views/downloads

205

DOI

10.5603/Hem.2019.0022

Keywords

Hodgkin lymphoma
high-dose chemotherapy
brentuximab vedotin

Authors

Beata Kania-Zembaczyńska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.